These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12503832)

  • 1. The effects of reboxetine, a noradrenaline reuptake inhibitor, on the plasma noradrenaline response to a cold pressor test in healthy volunteers.
    Kelly CB; McAree S; Cooper SJ; Stevenson M
    J Psychopharmacol; 2002 Dec; 16(4):333-6. PubMed ID: 12503832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans.
    Mayer AF; Schroeder C; Heusser K; Tank J; Diedrich A; Schmieder RE; Luft FC; Jordan J
    Hypertension; 2006 Jul; 48(1):120-6. PubMed ID: 16717144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance.
    Schroeder C; Tank J; Boschmann M; Diedrich A; Sharma AM; Biaggioni I; Luft FC; Jordan J
    Circulation; 2002 Jan; 105(3):347-53. PubMed ID: 11804991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noradrenaline might enhance assertive human social behaviours: an investigation in a flatmate relationship.
    Tse WS; Bond AJ
    Pharmacopsychiatry; 2006 Sep; 39(5):175-9. PubMed ID: 16944408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analgesic effect of the selective noradrenaline reuptake inhibitor reboxetine].
    Schüler P; Seibel K; Chevts V; Schaffler K
    Nervenarzt; 2002 Feb; 73(2):149-54. PubMed ID: 11975091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic reboxetine desensitizes terminal but not somatodendritic alpha2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus.
    Parini S; Renoldi G; Battaglia A; Invernizzi RW
    Neuropsychopharmacology; 2005 Jun; 30(6):1048-55. PubMed ID: 15668723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
    Hysek CM; Simmler LD; Ineichen M; Grouzmann E; Hoener MC; Brenneisen R; Huwyler J; Liechti ME
    Clin Pharmacol Ther; 2011 Aug; 90(2):246-55. PubMed ID: 21677639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reboxetine promotes social bonding in healthy volunteers.
    Tse WS; Bond AJ
    J Psychopharmacol; 2003 Jun; 17(2):189-95. PubMed ID: 12870566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation.
    Strempel S; Schroeder C; Hemmersbach R; Boese A; Tank J; Diedrich A; Heer M; Luft FC; Jordan J
    J Appl Physiol (1985); 2008 Mar; 104(3):756-60. PubMed ID: 18187607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects.
    Metzger CD; Wiegers M; Walter M; Abler B; Graf H
    Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26209860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute reboxetine administration increases plasma and salivary cortisol.
    Hill SA; Taylor MJ; Harmer CJ; Cowen PJ
    J Psychopharmacol; 2003 Sep; 17(3):273-5. PubMed ID: 14513918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers.
    Siepmann M; Mück-Weymann M; Joraschky P; Kirch W
    Psychopharmacology (Berl); 2001 Sep; 157(2):202-7. PubMed ID: 11594447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of noradrenergic activity on temporal information processing in humans.
    Rammsayer TH; Hennig J; Haag A; Lange N
    Q J Exp Psychol B; 2001 Aug; 54(3):247-58. PubMed ID: 11547514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action.
    Page ME; Brown K; Lucki I
    Psychopharmacology (Berl); 2003 Jan; 165(2):194-201. PubMed ID: 12426668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting response: noradrenaline reuptake inhibition.
    Montgomery SA
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition.
    Tank J; Schroeder C; Diedrich A; Szczech E; Haertter S; Sharma AM; Luft FC; Jordan J
    Circulation; 2003 Jun; 107(23):2949-54. PubMed ID: 12796139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difference in serotonergic and noradrenergic regulation of human social behaviours.
    Tse WS; Bond AJ
    Psychopharmacology (Berl); 2002 Jan; 159(2):216-21. PubMed ID: 11862352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No influence of noradrenaline manipulation on acute exercise-induced increase of brain-derived neurotrophic factor.
    Goekint M; Heyman E; Roelands B; Njemini R; Bautmans I; Mets T; Meeusen R
    Med Sci Sports Exerc; 2008 Nov; 40(11):1990-6. PubMed ID: 18845978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reboxetine-induced increase of accumbal dopamine efflux is inhibited by l-propranolol: a microdialysis study with freely moving rats.
    Mizoguchi N; Saigusa T; Aono Y; Sekino R; Takada K; Oi Y; Ueda K; Koshikawa N; Cools AR
    Eur J Pharmacol; 2008 Dec; 601(1-3):94-8. PubMed ID: 18996113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No effects of enhanced central norepinephrine on finger-sequence learning and attention.
    Plewnia C; Hoppe J; Gerloff C
    Psychopharmacology (Berl); 2006 Aug; 187(2):260-5. PubMed ID: 16767410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.